|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
CN117043167A
(zh)
*
|
2021-03-17 |
2023-11-10 |
劲方医药科技(上海)有限公司 |
嘧啶并环类化合物及其制法和用途
|
|
MX2023015533A
(es)
*
|
2021-06-21 |
2024-01-23 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
|
|
CN115557974A
(zh)
*
|
2021-07-02 |
2023-01-03 |
上海迪诺医药科技有限公司 |
Kras g12d抑制剂及其应用
|
|
TW202315626A
(zh)
*
|
2021-08-31 |
2023-04-16 |
大陸商勁方醫藥科技(上海)有限公司 |
嘧啶并環類化合物及其製法和用途
|
|
CN118019746A
(zh)
*
|
2021-09-27 |
2024-05-10 |
北京加科思新药研发有限公司 |
多环稠环衍生物及其用途
|
|
WO2023103906A1
(zh)
*
|
2021-12-07 |
2023-06-15 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
JP2025504041A
(ja)
*
|
2022-01-30 |
2025-02-06 |
シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド |
キノリン系化合物及びその使用
|
|
EP4491673A4
(en)
*
|
2022-03-08 |
2026-03-18 |
Shinetsu Chemical Co |
TWO-COMPONENT ADDITION-CURDED THERMOCONDUCTIVE SILICONE COMPOSITION, AND A HARDENED SILICONE OBJECT THEREIN
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
CN119365467A
(zh)
|
2022-05-19 |
2025-01-24 |
基因泰克公司 |
氮杂-四环氧氮杂䓬化合物及其用途
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024008178A1
(zh)
*
|
2022-07-08 |
2024-01-11 |
贝达药业股份有限公司 |
Kras g12d抑制剂及其在医药上的应用
|
|
CN117430620A
(zh)
*
|
2022-07-22 |
2024-01-23 |
上海医药集团股份有限公司 |
嘧啶环类化合物、其中间体、其药物组合物及其应用
|
|
TW202409051A
(zh)
|
2022-07-27 |
2024-03-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠環類化合物、其製備方法及其在醫藥上的應用
|
|
AU2023320565A1
(en)
|
2022-08-05 |
2025-01-23 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2024041621A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Jacobio Pharmaceuticals Co., Ltd. |
K-ras mutant protein inhibitors
|
|
WO2024041573A1
(en)
*
|
2022-08-25 |
2024-02-29 |
Zai Lab (Shanghai) Co., Ltd. |
Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof
|
|
WO2024051721A1
(en)
*
|
2022-09-07 |
2024-03-14 |
Nikang Therapeutics, Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
WO2024138486A1
(en)
*
|
2022-12-29 |
2024-07-04 |
Nikang Therapeutics, Inc. |
Tetracyclic derivatives as kras inhibitors
|
|
TW202426459A
(zh)
*
|
2022-09-23 |
2024-07-01 |
大陸商勁方醫藥科技(上海)有限公司 |
嘧啶并環類化合物及其製法和用途
|
|
JP2025532125A
(ja)
*
|
2022-09-23 |
2025-09-29 |
アイディーエンス カンパニー リミテッド |
新規なテトラヘテロサイクル化合物
|
|
TW202440594A
(zh)
*
|
2022-12-07 |
2024-10-16 |
大陸商北京加科思新藥研發有限公司 |
稠環化合物及其用途
|
|
JP2025541435A
(ja)
*
|
2022-12-23 |
2025-12-18 |
上海和誉生物医薬科技有限公司 |
Ｋｒａｓ ｇ１２ｄ阻害剤及びその応用
|
|
WO2024149214A1
(en)
*
|
2023-01-10 |
2024-07-18 |
Nikang Therapeutics, Inc. |
Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway
|
|
CN122187841A
(zh)
*
|
2023-01-18 |
2026-06-12 |
苏州赞荣医药科技有限公司 |
Kras g12d抑制剂和其用途
|
|
CN120548318A
(zh)
*
|
2023-01-18 |
2025-08-26 |
苏州赞荣医药科技有限公司 |
Kras g12d抑制剂和其用途
|
|
CN120500487A
(zh)
*
|
2023-01-18 |
2025-08-15 |
上海艾力斯医药科技股份有限公司 |
杂环类化合物、其药物组合物及其用途
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
WO2024178304A1
(en)
*
|
2023-02-24 |
2024-08-29 |
Alterome Therapeutics, Inc. |
Kras modulators
|
|
CN121487738A
(zh)
|
2023-03-30 |
2026-02-06 |
锐新医药公司 |
诱导ras gtp水解的组合物和其用途
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
CN121487951A
(zh)
|
2023-04-07 |
2026-02-06 |
锐新医药公司 |
大环ras抑制剂
|
|
EP4695261A1
(en)
|
2023-04-14 |
2026-02-18 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
AU2024251341A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
EP4716531A2
(en)
*
|
2023-05-22 |
2026-04-01 |
Board of Regents, The University of Texas System |
Heterocyclic compounds as nras inhibitors
|
|
CN121843945A
(zh)
*
|
2023-07-18 |
2026-04-10 |
泰励生物科技（上海）有限公司 |
具有抗kras突变肿瘤活性的化合物
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
CN117430564A
(zh)
*
|
2023-10-18 |
2024-01-23 |
爱斯特（成都）生物制药股份有限公司 |
一种7-溴-2,6-二氯-5,8-二氟噻唑啉-4(3h)-酮的制备方法
|
|
TW202540122A
(zh)
*
|
2023-11-22 |
2025-10-16 |
美商建南德克公司 |
Ｋｒａｓ－ｇ１２ｄ之氮雜－四環氧氮呯抑制劑的多晶型物及合成方法
|
|
CN119684315B
(zh)
*
|
2024-01-26 |
2026-05-12 |
苏州盛迪亚生物医药有限公司 |
一种苯并噻吩取代稠环化合物的结晶形式及其制备方法
|
|
CN119490512B
(zh)
*
|
2024-01-26 |
2026-06-16 |
苏州盛迪亚生物医药有限公司 |
一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途
|
|
WO2025157261A1
(zh)
*
|
2024-01-26 |
2025-07-31 |
江苏恒瑞医药股份有限公司 |
G12d抑制剂化合物晶型及其制备方法
|
|
CN119661555B
(zh)
*
|
2024-01-26 |
2026-04-14 |
苏州盛迪亚生物医药有限公司 |
一种稠环类化合物的可药用盐、其结晶形式及用途
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025209456A1
(zh)
*
|
2024-04-03 |
2025-10-09 |
北京泰德制药股份有限公司 |
血管紧张素ii 2型受体拮抗剂及其用于治疗癌性疼痛的用途
|
|
TW202608891A
(zh)
*
|
2024-04-19 |
2026-03-01 |
大陸商領泰生物醫藥（紹興）有限公司 |
Ｋｒａｓ ｇ１２ｄ降解劑及其製備方法與應用
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025256655A1
(zh)
*
|
2024-06-14 |
2025-12-18 |
上海翰森生物医药科技有限公司 |
一种含嘧啶多元并环类衍生物抑制剂的晶型及其制备方法
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026073024A1
(en)
*
|
2024-09-30 |
2026-04-02 |
Gilead Sciences, Inc. |
Kras g12d inhibitors for the treatment of cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|